Interaction Checker

Interacciones de Irinotecán

Irinotecán (Camptosar, Onivyde) tiene 137 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 113; moderadas: 21; leves: 2; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 1. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (113)

  • Acetazolamidainhibidor de la anhidrasa carbónicaGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Ácido etacrínicodiurético de asaGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Amiloridadiurético ahorrador de potasioGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • AmiodaronaantiarrítmicoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Aprepitantinhibidor de CYP3A4Grave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • AtazanavirantirretroviralGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Atenolol y clortalidonabetabloqueanteGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • AtropinaanticolinérgicoGrave

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (etiqueta de Irinotecán, Advertencia en recuadro)

  • Atropina y pralidoximaanticolinérgicoGrave

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (etiqueta de Irinotecán, Advertencia en recuadro)

  • Benazepril e hidroclorotiazidainhibidor de la ECAGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Betanecolagonista colinérgicoGrave

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (etiqueta de Irinotecán, Advertencia en recuadro)

  • BisacodilolaxanteGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Bisoprolol e hidroclorotiazidabetabloqueanteGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Bosentáninductor de CYP3A4Grave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Bumetanidadiurético de asaGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • CarbamazepinaanticonvulsivoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Cevimelinaagonista colinérgicoGrave

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (etiqueta de Irinotecán, Advertencia en recuadro)

  • CiclosporinainmunosupresorGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Grave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • ClobazambenzodiazepinaGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Clorotiazidadiurético tiazídicoGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Clortalidonadiurético tiazídicoGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • DarunavirantirretroviralGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Darunavir y cobicistatantirretroviralGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • DexametasonacorticosteroideGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Difenoxilato y atropinaGrave

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (etiqueta de Irinotecán, Advertencia en recuadro)

  • Difenoxina y atropinaGrave

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (etiqueta de Irinotecán, Advertencia en recuadro)

  • Diltiazembloqueador de los canales de calcioGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • DocusatolaxanteGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • DronedaronaantiarrítmicoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • EfavirenzantirretroviralGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Efavirenz, lamivudina y tenofovirantirretroviralGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Enalapril e hidroclorotiazidainhibidor de la ECAGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Eplerenonaantagonista de la aldosteronaGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Eritromicinaantibiótico macrólidoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • EscopolaminaanticolinérgicoGrave

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (etiqueta de Irinotecán, Advertencia en recuadro)

  • EslicarbazepinaanticonvulsivoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Espironolactonaantagonista de la aldosteronaGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • EtravirinaantirretroviralGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • EverolimusinmunosupresorGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Fenobarbital, hiosciamina, atropina y escopolaminabarbitúricoGrave

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (etiqueta de Irinotecán, Advertencia en recuadro)

  • Fentermina y topiramatoestimulante del SNCGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Fluconazolantifúngico azólicoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • FosamprenavirantirretroviralGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Fosaprepitantinhibidor de CYP3A4Grave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • FosfenitoínaanticonvulsivoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Fosinopril e hidroclorotiazidainhibidor de la ECAGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Furosemidadiurético de asaGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • GriseofulvinaantifúngicoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Hidroclorotiazidadiurético tiazídicoGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Imatinibinhibidor de CYP3A4Grave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Indapamidadiurético tiazídicoGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • IsoniazidaantibióticoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Itraconazolantifúngico azólicoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Ivacaftorinhibidor de CYP3A4Grave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Ketoconazolantifúngico azólicoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • LactulosalaxanteGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • LenacapavirantirretroviralGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Loperamidafármaco que prolonga el intervalo QTGrave

    Late diarrhea can be life threatening and should be treated promptly with loperamide. (etiqueta de Irinotecán, Advertencia en recuadro)

  • Lopinavir y ritonavirantirretroviralGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Lorlatinibinductor de CYP3A4Grave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Metolazonadiurético tiazídicoGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Metoprolol e hidroclorotiazidabetabloqueanteGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Mifepristonainhibidor de CYP3A4Grave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Mitapivatinductor de CYP3A4Grave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Grave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Nafcilinaantibiótico del grupo de las penicilinasGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • NefazodonaantidepresivoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • NevirapinaantirretroviralGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • OxcarbazepinaanticonvulsivoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Grave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • PerampanelanticonvulsivoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Pilocarpinaagonista colinérgicoGrave

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (etiqueta de Irinotecán, Advertencia en recuadro)

  • Piridostigminainhibidor de la colinesterasaGrave

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (etiqueta de Irinotecán, Advertencia en recuadro)

  • Polietilenglicol 3350laxanteGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Posaconazolantifúngico azólicoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • PrimidonaanticonvulsivoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Quinapril e hidroclorotiazidainhibidor de la ECAGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Ranolazinafármaco que prolonga el intervalo QTGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • RifabutinaantibióticoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • RifampicinaantibióticoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • RifapentinaantibióticoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • RitonavirantirretroviralGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Sen (senósidos)laxanteGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Sofosbuvir y velpatasvirantiviralGrave

    Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (etiqueta de Sofosbuvir y velpatasvir, Interacciones medicamentosas)

  • Suvorexantsedante-hipnóticoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Suzetriginainductor de CYP3A4Grave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Ticagrelorantiagregante plaquetarioGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • TopiramatoanticonvulsivoGrave

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Torasemidadiurético de asaGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Triamterenodiurético ahorrador de potasioGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioGrave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Avoid diuretics or laxatives in patients with diarrhea. (etiqueta de Irinotecán, Advertencias y precauciones)

  • Verapamilobloqueador de los canales de calcioGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Voriconazolantifúngico azólicoGrave

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

Interacciones moderadas (21)

  • Ácido valproicoanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • BrivaracetamanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Cannabidiol (con receta)anticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • CapecitabinaantimetabolitoModerada

    Closely monitor for signs of renal toxicity when XELODA is used concomitantly with nephrotoxic drugs (e.g. platinum salts, irinotecan, methotrexate, intravenous bisphosphonates). (etiqueta de Capecitabina, Interacciones medicamentosas)

  • ClonazepambenzodiazepinaModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Divalproato de sodio (valproato)anticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Eltrombopaginhibidor de OATP1B1Moderada

    …(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (etiqueta de Eltrombopag, Interacciones medicamentosas)

  • EtosuximidaanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • FelbamatoanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • GabapentinaanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • GemfibrozilofibratoModerada

    Coadministration of CAMPTOSAR with other inhibitors of CYP3A4 (e.g., clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir) may increase systemic exposure to irinotecan or SN-38. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • LacosamidaanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • LamotriginaanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • LevetiracetamanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • MesuximidaanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • PregabalinaanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • Rolapitantinhibidor de CYP2D6Moderada

    BCRP Substrates with a Narrow Therapeutic Index (e.g., methotrexate, topotecan, or irinotecan) Clinical Impact: Increased plasma concentrations of BCRP substrates (e.g., methotrexate, topotecan, or irinotecan) may result in potential adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Rolapitant, Interacciones medicamentosas)

  • RufinamidaanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • TiagabinaanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • VigabatrinaanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • ZonisamidaanticonvulsivoModerada

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (etiqueta de Irinotecán, Interacciones medicamentosas)

Menciones leves (2)

  • Ácido folínico (leucovorina)Leve

    5-Fluorouracil (5-FU) and Leucovorin (LV) In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. (etiqueta de Irinotecán, Interacciones medicamentosas)

  • FluorouraciloantimetabolitoLeve

    5-Fluorouracil (5-FU) and Leucovorin (LV) In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. (etiqueta de Irinotecán, Interacciones medicamentosas)

Sin interacción significativa según la etiqueta (1)

  • BevacizumabSin interacción

    Effects of VEGZELMA on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; however, 3 of the 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel… (etiqueta de Bevacizumab, Interacciones medicamentosas)

Compruebe Irinotecán frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.